Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price boosted by equities researchers at Citigroup from $54.00 to $62.00 in a research report issued on Thursday. The firm currently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup‘s price target would indicate a potential upside of 2.43% from the stock’s current price.
A number of other research firms have also recently commented on RARE. ValuEngine upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday. BidaskClub upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Wednesday. Credit Suisse Group restated a “hold” rating and set a $59.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday. Raymond James upped their price target on Ultragenyx Pharmaceutical from $53.00 to $57.00 and gave the stock a “buy” rating in a research note on Tuesday, November 6th. Finally, Canaccord Genuity decreased their price target on Ultragenyx Pharmaceutical from $90.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, November 7th. Seven analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $75.28.
RARE opened at $60.53 on Thursday. Ultragenyx Pharmaceutical has a one year low of $37.44 and a one year high of $90.98. The company has a market capitalization of $2.87 billion, a P/E ratio of -8.19 and a beta of 2.26.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) EPS for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.01. Ultragenyx Pharmaceutical had a negative return on equity of 34.15% and a negative net margin of 383.75%. The firm had revenue of $16.26 million for the quarter, compared to analysts’ expectations of $13.30 million. Equities analysts anticipate that Ultragenyx Pharmaceutical will post -6.49 EPS for the current fiscal year.
In other news, Director William Aliski sold 6,000 shares of the stock in a transaction on Friday, December 7th. The stock was sold at an average price of $49.69, for a total value of $298,140.00. Following the sale, the director now directly owns 72,610 shares in the company, valued at $3,607,990.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 8.40% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of RARE. Dimensional Fund Advisors LP purchased a new position in Ultragenyx Pharmaceutical in the second quarter valued at $587,000. Bank of America Corp DE increased its holdings in Ultragenyx Pharmaceutical by 62.2% in the second quarter. Bank of America Corp DE now owns 65,791 shares of the biopharmaceutical company’s stock valued at $5,058,000 after buying an additional 25,219 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in Ultragenyx Pharmaceutical in the second quarter valued at $181,000. Bank of New York Mellon Corp increased its holdings in Ultragenyx Pharmaceutical by 1.9% in the second quarter. Bank of New York Mellon Corp now owns 207,662 shares of the biopharmaceutical company’s stock valued at $15,963,000 after buying an additional 3,903 shares during the last quarter. Finally, First Trust Advisors LP increased its holdings in Ultragenyx Pharmaceutical by 29.3% in the third quarter. First Trust Advisors LP now owns 1,263,466 shares of the biopharmaceutical company’s stock valued at $96,453,000 after buying an additional 285,961 shares during the last quarter. 98.35% of the stock is currently owned by hedge funds and other institutional investors.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.
Further Reading: Why is a lock-up period needed for an IPO?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.